🇺🇸 FDA
Patent

US 10501742

Compositions and methods for inhibiting expression of the PCSK9 gene

granted A61KA61K31/713A61P

Quick answer

US patent 10501742 (Compositions and methods for inhibiting expression of the PCSK9 gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/713, A61P, A61P3/06, A61P43/00